BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition
By FormBlends Medical Team · Last updated: April 25, 2026
BI 3034701 is the more disciplined early-development story. NA-931 is the more ambitious one. If you think obesity winners will still come from relatively controlled multi-agonist engineering, BI 3034701 is easier to underwrite. If you think the field keeps rewarding bigger mechanism swings, NA-931 is the bolder watch.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory. BI 3034701 is usually a better fit for readers who prefer an early but still relatively disciplined multi-agonist bet, while NA-931 (Bioglutide) is usually a better fit for readers watching whether more extreme receptor stacking can actually survive development. Cost also matters: BI 3034701 is listed at Early trial-stage asset; pricing unknown, while NA-931 (Bioglutide) is listed at Trial-stage asset; pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
BI 3034701
Pipeline Compound
Strengths
- Backed by Boehringer and Gubra with a real obesity-development infrastructure behind it
- Represents a more disciplined early triple-agonist pathway bet
- Still early enough to improve sharply if human data is clean
Weaknesses
- Only Phase 1, so there is still major development risk
- Less headline novelty than a more aggressive receptor stack
Best For
Readers who prefer an early but still relatively disciplined multi-agonist bet.
Typical Cost
Early trial-stage asset; pricing unknown
NA-931 (Bioglutide)
Pipeline Compound
Strengths
- Quadruple-mechanism ambition makes it one of the more aggressive designs in the field
- Already Phase 2, which matters given how experimental the biology sounds
- Could become important if stacked-receptor programs keep outperforming expectations
Weaknesses
- The more ambitious the receptor stack, the more skepticism it invites on tolerability and manufacturability
- Sponsor visibility is lower than the large-cap leaders
Best For
Readers watching whether more extreme receptor stacking can actually survive development.
Typical Cost
Trial-stage asset; pricing unknown
Key Differences
- 1BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory
- 2NA-931 is further along on paper, but it also carries a more aggressive design risk
- 3Boehringer/Gubra gives BI 3034701 a stronger big-company development context
- 4This comparison is mostly about disciplined complexity versus maximal complexity
Frequently Asked Questions
What is the difference between BI 3034701 and NA-931 (Bioglutide)?
BI 3034701 is an early triple-agonist program, while NA-931 pushes into quadruple-mechanism territory. NA-931 is further along on paper, but it also carries a more aggressive design risk.
Which is more effective, BI 3034701 or NA-931 (Bioglutide)?
BI 3034701 is the more disciplined early-development story. NA-931 is the more ambitious one. If you think obesity winners will still come from relatively controlled multi-agonist engineering, BI 3034701 is easier to underwrite. If you think the field keeps rewarding bigger mechanism swings, NA-931 is the bolder watch.
How much does BI 3034701 cost compared to NA-931 (Bioglutide)?
BI 3034701 typically costs Early trial-stage asset; pricing unknown, while NA-931 (Bioglutide) typically costs Trial-stage asset; pricing unknown.
Who should choose BI 3034701 over NA-931 (Bioglutide)?
BI 3034701 is best for: Readers who prefer an early but still relatively disciplined multi-agonist bet.. NA-931 (Bioglutide) is best for: Readers watching whether more extreme receptor stacking can actually survive development..
Ready to get started?
Connect with a licensed provider who can help you decide between BI 3034701 and NA-931 (Bioglutide) based on your goals, health history, and budget.